Among 77,758 propensity-matched patients with type 2 diabetes and heart failure with reduced ejection fraction (HFrEF), GLP-1 receptor agonist (GLP-1 RA) therapy was associated with a striking 60% reduction in all-cause mortality (4.2% vs. 12%; HR 0.40) and a 40% reduction in a composite of acute myocardial infarction, ischemic stroke, and acute heart failure exacerbation (32.5% vs. 48.3%; HR 0.60) over one year. The absolute mortality risk difference of 7.8 percentage points is clinically substantial.
This finding challenges the cautious stance historically taken toward GLP-1 RAs in HFrEF, where concerns about heart rate elevation and uncertain mechanistic benefit led to their de-prioritization compared to SGLT-2 inhibitors and sacubitril/valsartan. If confirmed, these results would fundamentally reshape combination therapy protocols for this high-risk dual-diagnosis population. However, several limitations demand careful scrutiny. The retrospective design using the TriNetX federated database introduces unmeasured confounding — GLP-1 RA users may represent a healthier, more medication-adherent subgroup despite propensity matching. The unusually short drug initiation window (May 13 to June 6, 2026 — just 24 days) raises questions about cohort representativeness and data completeness. Effect sizes of this magnitude are rare in cardiovascular medicine and warrant replication in randomized trials. Critically, this is a preprint posted on medRxiv and has not yet undergone peer review — the dramatic findings should be interpreted cautiously until independent validation.
